Nanoparticle-based delivery enhances anti-inflammatory effect of low molecular weight heparin in experimental ulcerative colitis

References

• Ali ME, Lamprecht A. (2014). Spray freeze drying for dry powder inhalation of nanoparticles. Eur J Pharm Biopharm 87:510–17
   PubMed Web of Science ®Google Scholar
• Carmichael J, DeGraff WG, Gazdar AF, et al. (1987). Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47:936–42
   PubMed Web of Science ®Google Scholar
• Celasco G, Moro L, Bozzella R, et al. (2008). Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci 53:3170–5
   PubMed Web of Science ®Google Scholar
• Celasco G, Papa A, Jones R, et al. (2010). Clinical trial: oral colon-release parnaparin sodium tablets (CB-01-05 MMX) for active left-sided ulcerative colitis. Aliment Pharmacol Ther 31:375–86
   PubMed Web of Science ®Google Scholar
• Chande N, McDonald JW, Macdonald JK, Wang JJ. (2010). Unfractionated or low-molecular weight heparin for induction of remission in ulcerative colitis. Cochrane Database Syst Rev: CD006774
   PubMed Web of Science ®Google Scholar
• Demoré B, Benoit E, Maincent P, et al. (1998). Determination of heparin in aqueous solutions. J Clin Pharm Ther 23:381–4
   PubMed Web of Science ®Google Scholar
• Dotan I, Hershkoviz R, Karmeli F, et al. (2001). Heparin and low-molecular-weight heparin (enoxaparin) significantly ameliorate experimental colitis in rats. Aliment Pharmacol Ther 15:1687–97
   PubMed Web of Science ®Google Scholar
• Hartmann G, Bidlingmaier C, Siegmund B, et al. (2000). Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice. J Pharmacol Exp Ther 292:22–30
   PubMed Web of Science ®Google Scholar
• Hazemi P, Tzotzos SJ, Fischer B, et al. (2010). Essential structural features of TNF-α lectin-like domain derived peptides for activation of amiloride-sensitive sodium current in A549 cells. J Med Chem 53:8021–9
   PubMed Web of Science ®Google Scholar
• Jiao Y, Ubrich N, Marchand-Arvier M, et al. (2002). In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 105:230–5
   PubMed Web of Science ®Google Scholar
• Kaser A, Zeissig S, Blumberg RS. (2010). Inflammatory Bowel disease. Ann Rev Immunol 28:573–621
   PubMed Web of Science ®Google Scholar
• Krawisz JE, Sharon P, Stenson WF. (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87:1344–50
   PubMed Web of Science ®Google Scholar
• Lai SK, Wang Y-Y, Hanes J. (2009). Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61:158–71
   PubMed Web of Science ®Google Scholar
• Lamprecht A. (2015). Nanomedicines in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 12:195–204
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Koenig P, Ubrich N, et al. (2006). Low molecular weight heparin nanoparticles: mucoadhesion and behaviour in Caco-2 cells. Nanotechnology 17:3673
   Web of Science ®Google Scholar
• Lamprecht A, Schäfer U, Lehr CM. (2001). Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 18:788–93
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y. (2005). Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J Pharmacol Exp Ther 315:196–202
   PubMed Web of Science ®Google Scholar
• Lean QY, Eri RD, Randall-Demllo S, et al. (2015b). Orally administered enoxaparin ameliorates acute colitis by reducing macrophage-associated inflammatory responses. PLoS One 10:e0134259
   PubMed Web of Science ®Google Scholar
• Lean QY, Gueven N, Eri RD, et al. (2015a). Heparins in ulcerative colitis: proposed mechanisms of action and potential reasons for inconsistent clinical outcomes. Expert Rev Clin Pharmacol 8:795–811
   PubMed Web of Science ®Google Scholar
• Luo J, Cao J, Jiang X, Cui H. (2010). Effect of low molecular weight heparin rectal suppository on experimental ulcerative colitis in mice. Biomed Pharmacother 64:441–5
   PubMed Web of Science ®Google Scholar
• Luo J-Y, Zhong Y, Cao J-C, Cui H-F. (2011). Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis. Biomed Pharmacother 65:111–17
   PubMed Web of Science ®Google Scholar
• McAlindon ME, Hawkey CJ, Mahida YR. (1998). Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut 42:214–19
   PubMed Web of Science ®Google Scholar
• Michell NP, Lalor P, Langman MJ. (2001). Heparin therapy for ulcerative colitis? Effects and mechanisms. Eur J Gastroenterol Hepatol 13:449–56
   PubMed Web of Science ®Google Scholar
• Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. (1999). Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm 187:143–52
   PubMed Web of Science ®Google Scholar
• Nakase H, Okazaki K, Tabata Y, et al. (2001). An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. J Pharmacol Exp Ther 297:1122–8
   PubMed Web of Science ®Google Scholar
• Niebel W, Walkenbach K, Béduneau A, et al. (2012). Nanoparticle-based clodronate delivery mitigates murine experimental colitis. J Control Rel 160:659–65
   PubMed Web of Science ®Google Scholar
• Pellequer Y, Meissner Y, Ubrich N, Lamprecht A. (2007). Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther 321:726–33
   PubMed Web of Science ®Google Scholar
• Pertuit D, Moulari B, Betz T, et al. (2007). 5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J Control Rel 123:211–18. Podolsky DK. (2002). Inflammatory bowel disease. New Engl J Med 347:417–29
   PubMed Web of Science ®Google Scholar
• Törkvist L, Thorlacius H, Sjöqvist U, et al. (1999). Low molecular weight heparin as adjuvant therapy in active ulcerative colitis. Aliment Pharmacol Ther 13:1323–8
   PubMed Web of Science ®Google Scholar
• Viehof A, Lamprecht A. (2013). Oral delivery of low molecular weight heparin by polyaminomethacrylate coacervates. Pharm Res 30:1990–8
   PubMed Web of Science ®Google Scholar
• Vrij AA, Jansen JM, Schoon EJ, et al. (2001). Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi. Scand J Gastroenterol: 41–7
   Web of Science ®Google Scholar
• Wachsmann P, Moulari B, Béduneau A, et al. (2013). Surfactant-dependence of nanoparticle treatment in murine experimental colitis. J Control Rel 172:62–8
   PubMed Web of Science ®Google Scholar
• Wang Y-Y, Lai SK, So C, et al. (2011). Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS One 6:e21547
   PubMed Web of Science ®Google Scholar
• Weisser SB, Brugger HK, Voglmaier NS, et al. (2011). SHIP-deficient, alternatively activated macrophages protect mice during DSS-induced colitis. J Leukocyte Biol 90:483–92
   PubMed Web of Science ®Google Scholar
• Yang H, Taylor KD, Rotter JI. (2001). Inflammatory Bowel disease: I. Genet Epidemiol Mol Genet Metab 74:1–21
   PubMed Web of Science ®Google Scholar
• Zhu W, Yu J, Nie Y, et al. (2014). Disequilibrium of M1 and M2 macrophages correlates with the development of experimental inflammatory bowel diseases. Immunol Invest 43:638–52
   PubMed Web of Science ®Google Scholar